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Abstract 
 
In this article, the authors provide a narrative review of the mounting evidence base on personality disorder in childhood 
and adolescence. Topics covered include diagnostic validity, prevalence, developmental issues, comorbidity, risk and 
protective factors, and treatment. Novel indicated prevention and early intervention programs for borderline personality 
disorder in adolescence are given special priority. To conclude, directions for future research are provided.  
 
Keywords: personality disorder; adolescence; diagnosis; early intervention; developmental psychopathology; psychotherapy; 
prevention 
 
 
 
Introduction 
Until recently, personality disorder (PD) was 
considered separately from other mental state 
disorders as a special and intractable form of adult 
mental disorder with a primarily environmental 
aetiology and a treatment refractory course (1,2). To 
paraphrase the Danish philosopher Søren 
Kierkegaard (3), it was as if PD was a sickness unto 
death. Fortunately, such beliefs—together with the 
associated therapeutic nihilism—have now been 
dispelled by empirical research. In adult mental 
health, PD is now widely recognized as a major 
mental disorder that is associated with severe 
psychosocial dysfunction and poor quality of life. 
Moreover, PD has come to be considered treatable 
and, in some cases, even to remit (4,5). This 
heightened recognition of PD is also reflected in the 
international proliferation of official treatment 
guidelines (6-9).  
For decades, there has been general agreement, as 
reflected in the official diagnostic manuals, that PD 
has its onset at least by adolescence or early 
adulthood (10,11). By implication, this develop-
mental perspective on PD opens up the possibility 
of identifying PD among children and young 
people. Historically, however, PD during childhood 
and adolescence has been a neglected area of 
empirical research and surrounded by controversy 
(12-17). Fortunately, research on PD in childhood 
and adolescence has flourished over the past two 
decades and shed light on many of the persistent 
clinical controversies and myths that surround these 
syndromes. 
Despite the remarkable scientific progress of the 
past two decades, skepticism, unease, and 
misunderstanding with regard to PD diagnoses in 
adolescence seem to continue among some 
clinicians (18-21). Hence, a major goal of this 
special issue of the Scandinavian Journal of Child 
and Adolescent Psychiatry and Psychology is to 
increase researchers’ and clinicians’ awareness of the 
validity and importance of PD during adolescence 
so that it might be more readily identified and 
treated. We hope that this article, which reviews the 
current evidence base and offer suggestions for 
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future research, will help to ease some of these 
concerns by highlighting key research findings. 
 
Synopsis Research Findings 
 
Diagnosing personality disorder in children and 
adolescents 
A source of controversy and misunderstanding has 
been whether PD diagnoses can be made or are 
permitted for children and adolescents. A common 
misperception among mental health professionals is 
that the official diagnostic systems—the Diagnostic 
and Statistical Manual of Mental Disorders, Fifth Edition 
(DSM-5) (10) and the ICD-10 Classification of Mental 
and Behavioural Disorders (11)—do not permit PD 
diagnoses for individuals who are younger than 18 
years (21). One possible reason for this 
misunderstanding is the ambivalent and 
contradictory phrasing employed in the DSM-5 
(Section II) and the ICD-10 with regard to the 
diagnosis of PD in this age group. Despite the 
conceptualization of PD as a developmental 
disorder that usually has its onset by adolescence or 
early adulthood, the DSM-5 notes that PD diagnosis 
for individuals who are less than 18 years old should 
only be considered in “relatively unusual” 
circumstances (10) and ICD-10 considers the 
applicability of PD diagnoses in adolescence to be 
“highly unlikely” (11). The only exception to the 
allowance of diagnosing PD below age 18, is for 
antisocial PD, in the DSM-5, Section II, which 
explicitly requires individuals to be 18 years or 
older. Hence, despite allowing for PD diagnoses 
among individuals who are less than 18 years old, 
the use of such wording by the official diagnostic 
systems effectively discourages the use of this 
diagnosis. The DSM-5 confuses matters further by 
stating that the features of a PD only need to be 
present for one year when applying PD diagnoses to 
individuals who are less than 18 years old. This 
seems too short a period to accurately distinguish a 
mental state disorder from a PD (22). The division 
of the diagnostic manuals into separate sections on 
child and adolescent disorders versus adult 
disorders further contributes to the confusion. PD 
is not mentioned in the former but appears in the 
latter, with little account of its developmental 
origins and manifestations. The ICD-10 labeling of 
PDs as “Disorders of adult personality” is a case in 
point. As we demonstrate later in this review, such 
ideas enshrined in the current diagnostic manuals 
can no longer be supported. Section III of the 
DSM-5 and the forthcoming ICD-11 both reflect 
the progress made in understanding the reliability 
and validity of PD diagnoses (22) in childhood and 
adolescence, supporting the feasibility of their use 
and recognizing that they are as reliable and valid in 
young people as they are for adults (23-33).  
 
 
Prevalence 
Few studies have investigated the prevalence of PD 
in adolescence, and virtually none have looked at its 
prevalence in childhood. Extant studies have also 
used different sampling and assessment procedures. 
Accordingly, the prevalence data reviewed in this 
paragraph are at best tentative. The prevalence of 
PD in adolescent community samples and primary 
care settings generally ranges from 6% to 17% 
across studies (34). An exception to these estimates 
was a study by Lewinsohn and colleagues (35), 
which found a low prevalence of PD in the 
community (1.7% among participants without and 
3.8% among participants with a history of other 
mental disorders). The relatively low prevalence 
estimates in this study are probably a result of the 
researchers using the International Personality 
Disorder Examination (IPDE) (36) for assessments, 
which required PD features to be present for 5 
years, even in young people.  
Prevalence estimates in clinical samples range 
from 41% to 64% (27,37), and from 36% to 88% in 
juvenile justice samples (38-40). These prevalence 
estimates are similar to or slightly higher than those 
reported for adults (41-43). The peak prevalence for 
PD is reported to occur during early and middle 
adolescence (23,44), whereas studies that have 
focused on late adolescence have obtained lower 
prevalence estimates comparable to those reported 
for adults (34,45). Consistent with these findings a 
community-based longitudinal study of PD trait 
levels found that PD peaks in early adolescence and 
subsequently declines in a linear fashion until the 
late 20s (46). 
Additionally, studies have shown that, as in adult 
populations, the co-occurrence among specific PDs 
is frequent in adolescence (37,39,47,48). In terms of 
the DSM-5, Section II, grouping of PDs into three 
clusters on the basis of descriptive similarities, 
Cluster B PDs appear to be the most prevalent 
during adolescence (27,46), a finding that again 
converges with data for adult populations (49). 
 
Continuity and change in personality disorder 
Concerns about the temporal course of personality 
development are one possible source for the 
reticence of some clinicians to make PD diagnoses 
in adolescence. However, contemporary research 
has shown that personality development is a lifelong 
process, with no sudden changes occurring at age 
18, and that personality stability and change coexist 
across the life course (22). From a research 
perspective, there are multiple ways to concept-
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ualize the temporal course, continuity, and change 
of personality and its disorders throughout the life 
span (50-52). Here, we focus on the three most 
common methods used to do this: 1) rank-order 
continuity, 2) mean-level change, and 3) diagnostic 
stability.  
Rank-order continuity or differential continuity refers to 
the consistency of the relative order of individuals 
on a given PD dimension or symptom over time, 
typically expressed as a test-retest correlation. The 
rank-order stability of PD symptoms in adolescence 
and early adulthood has typically ranged from .42 
to .65 in longitudinal studies, thus indicating 
moderate to high stability (53,54). A longitudinal 
study that focused specifically on borderline PD 
features in childhood (in fourth through sixth 
graders) also reported moderate stability (55). A 
recent meta-analysis broadened these findings by 
showing that the rank-order stability of maladaptive 
personality traits and PD symptoms is moderately 
stable across childhood, increases in stability during 
early adolescence, and peaks in stability at around 
the age of 30 years (56).  
Mean-level change addresses the increase or decrease 
in the average trait level of the population as a 
whole. Studies of mean-level change indicate that 
mean levels of PD symptoms peaks during early 
adolescence and then decline throughout middle 
adolescence, reaching levels comparable with those 
of adults in late adolescence or early adulthood 
(34,46,54). Prospective studies also show that the 
deviation of maladaptive personality traits increases 
from late adolescence to early adulthood (53,57,58). 
This could indicate that the significance of PD 
symptoms changes over time in relation to salient 
life tasks and environmental demands (53,58-60). 
Data from large community samples suggest that 
specifically for borderline PD, mean levels of 
severity scores remain relatively stable for the ages 
of 14 through 17 (61,62).  
Diagnostic stability concerns the continuity of 
categorical PD diagnoses over time. Studies 
estimating the diagnostic stability of specific PDs in 
childhood and adolescence have generally reported 
low to moderate stability over time (23,24,34, 
61,63,64); this could be conservatively interpreted as 
indicating modest diagnostic stability during 
adolescence (65).  
How can we reconcile these research findings? To 
be sure, the issues surrounding the continuity and 
stability of PD are complex and unlikely to be easily 
resolved, for a number of reasons (66). First, we 
contextualize the results. Although diagnostic 
stability is low to moderate in adolescent popula-
tions, this is also the case in adulthood. A major 
finding from prospective follow-up studies of adult 
patients diagnosed with PDs is that diagnostic 
continuity is low to moderate, and that some 
patients even “remit” (22,51,67,68). However, 
diagnostic remission does not necessarily imply 
functional recovery (69). Indeed, most adult patients 
with PD who have been followed up for years 
remain significantly functionally impaired (5,67,70-
73). Persons displaying PD symptoms below the 
threshold for a categorical diagnosis are considered 
to have remitted diagnostically, but they might 
continue to have clinically significant levels of 
subthreshold personality pathology. Accordingly 
studies show that individuals diagnosed with PD in 
adolescence often still have elevated PD traits in 
adulthood (46,74). Also, individuals with persistent 
impairments might change from one diagnostic 
category to another over time (74), perhaps 
indicating “heterotypic continuity” – that the 
underlying developmental and pathological 
processes remains the same despite changes in 
phenotypic presentation (16,75-77). Overall, the 
bulk of current research converges on demon-
strating that persons diagnosed with PD in 
adolescence continue to have serious functional 
impairments well into adulthood (23,53,78,79).  
Second, the framework of developmental 
psychopathology (80,81) implies the findings can be 
interpreted in light of results from normal 
personality development. Research has convincingly 
demonstrated that normal and abnormal personality 
are part of the same spectrum, and display a similar 
higher-order factor structure across age groups 
(22,82-87). However, Western folk psychology 
generally views children and adolescents as having 
personalities that are unstable or “under con-
struction” whereas adult personalities are perceived 
as relatively unchanging (51,88). Research into 
normal personality development has challenged 
these assumptions by demonstrating that normal 
personality traits in childhood and adolescence, 
despite fluctuations within certain lower-order 
domains, are more stable than would commonly be 
expected, and also more stable than PD symptoms 
(87,89-92). Furthermore, contrary to common 
expectations, research reveals that normal person-
ality undergoes normative changes throughout the 
entire lifespan (93). Hence, some degree of 
development and change in personality is to be 
expected throughout the life course, as a result of 
the complex interactions between heritable 
dispositions and the environment (94-99).  
Third, it should be recognized that most 
longitudinal data on PD from childhood through 
adulthood stem from only one large prospective 
follow-up study, the Children in the Community 
(CIC) Study (53), and needs to be replicated (98). 
However, the findings of the CIC are consistent 
with cross-sectional prevalence studies of PDs 
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during early adolescence; results from studies of 
normal personality reporting age-related decreases 
in negative traits (51,100,101); and with findings 
from large-scale epidemiological studies which 
indicate that the onset for many common mental 
health disorders peaks during adolescence (102-
104). Given the continuity between PD criteria and 
normal personality traits, the research findings also 
beg the question of whether developmental changes 
in PD symptoms are part and parcel of the same 
process as the one that drives normal personality 
changes. Finally, it should be noted that other 
methodological issues relevant to understanding the 
PD continuity and change across the lifespan 
include the use of different assessment instruments 
and measurement error (56,98,105-109).  
To summarize, the current evidence shows a 
predictable pattern of stability and change in PD 
across the life course. PD seems to change from 
childhood through adulthood in similar ways to 
normal-range personality (22). In adolescence, as in 
adulthood, the rank order stability of PD is 
moderate to high, whereas diagnostic stability is 
low. The stability of functional impairments 
associated with PD is high across the lifespan. 
There is no sudden increase in trait stability in the 
transition from the second to third decade of life.  
 
Co-occurrence  
Research on PD in adults has consistently 
demonstrated that these conditions frequently co-
occur concurrently and prospectively with a wide 
range of other mental state disorders (110-112). 
This co-occurrence accounts for increases in 
impairment and treatment needs, higher rates of 
treatment seeking, poorer prognosis, and greater 
chronicity (113-117).  
Studies examining patterns of co-occurence in 
adolescent samples reveal that PD co-occur 
frequently with other mental disorders, such as 
affective and disruptive behavior disorders, post-
traumatic stress disorder (PTSD), eating disorders, 
substance abuse, anxiety disorders, and psychosis 
spectrum disorders (37,53,114,118-122). Research 
also suggests that adolescent in- and outpatients 
with co-occurring PD and mental state disorders are 
substantially more impaired than those with only 
mental state disorders (28,118), and tend to display 
the most complex patterns of comorbidity (120). 
Moreover, PD co-occuring with other mental 
disorders in adolescence has been prospectively 
linked with elevated mental health service use, and 
elevated use of prescribed psychotropic drugs 
during early adulthood (123). The presence of PD 
together with other mental disorders is also a 
significant predictor of poor quality of life (124).  
Data from the CIC Study have revealed that 
adolescents with co-occurring PD and other mental 
disorders have worse long-term prognoses for 
academic, occupational, and interpersonal 
functioning when followed for a period of more 
than 20 years (53,65,74). With regard to mental 
health outcomes, the CIC Study found that 
adolescents with co-occurring PD and mental state 
disorders had more severe current psychopathology 
and an almost nine-fold increase in the risk for 
future development of psychiatric disorders as 
compared with individuals with no disorders or 
those with only PDs or other mental disorders 
respectively (114). Additionally, reviews of major 
longitudinal studies suggest that PD co-occurring 
with other mental/behavioral disorders in 
adolescence increases the likelihood of PD 
continuing or worsening during young adulthood by 
up to 19 times and that it is more likely that 
improvement in PD leads to improvement in other 
co-occurring disorders than vice versa (51,53,57,65).  
 
Adverse outcomes and adaptive functioning 
Consistent with the literature on PD in adults (125-
127), the presence of PD in adolescents is 
concurrently and prospectively associated with an 
elevated risk for suicidal ideation and suicide 
attempts in early adulthood (128-130). Psychological 
autopsy studies of completed suicides among 
adolescents support these findings. One study 
found that PDs—especially those belonging to 
Cluster B and Cluster C—were more common 
among suicide victims than community controls 
(131). This is consistent with another psychological 
autopsy study, which also reported a large 
proportion of PDs among suicide completers; 
notably the investigators found that borderline PD 
was present in 33% of the cases (132). PD during 
adolescence is also associated with non-suicidal self-
injurious behavior such as cutting and burning (133-
135).  
PD in adolescence predicts conflictual romantic 
relationships (136), problems in friendships, poor 
educational achievements, problems at work 
(23,74,114,137,138), and problems with family 
members in early adulthood (34). PD in adolescence 
is also associated with high-risk sexual behaviors 
and a high number of sexual partners (139). Cluster 
A and Cluster B PDs in particular have been 
prospectively linked with an increased risk of 
violent and criminal behaviors in the community, 
during both adolescence and early adulthood 
(140,141). Cluster A PDs—most notably schizo-
typal PD—in childhood have been found to 
increase the risk for more severe schizophrenia 
spectrum disorders in adulthood (64), thereby 
reinforcing the view that Cluster A PDs, at least in 
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some cases, may represent developmental precur-
sors or prodromes to psychosis and schizophrenia 
spectrum disorders (53). 
Studies find that adolescents with borderline PD 
report significantly more mental health service use 
as compared with healthy controls (142). Borderline 
PD in early adolescence also prospectively predicts 
low social functioning and life satisfaction, fewer 
attained adult developmental milestones, and lower 
academic and occupational attainment, independent 
of other psychiatric disorders and despite age-
related borderline PD symptom decline over time 
(74). Finally, PD in adolescence significantly reduces 
concurrent and future quality of life (124,143), and 
increases the risk of unnatural and violent death 
amongst offenders (144). 
 
Risk and protective factors 
Until the last 15 years, most developmental studies 
of PD focused on early childhood experiences and 
how they affect later adult psychopathology. 
Although early childhood experiences are 
important, their effects on future development and 
outcomes are likely to be mediated or even reversed 
by later experiences (22,145), and there are currently 
only limited data to inform us about these 
processes. With regard to “distal” risk factors, most 
data come from the CIC Study. Low socioeconomic 
status in the family of origin, being raised by a single 
parent, receiving family welfare support, frequent 
parental conflicts, and parental illness or death have 
been identified as prospective risk factors for future 
development of PD (53,65). Maladaptive family 
functioning and parenting, including low emotional 
closeness between parent and child, use of harsh 
punishment during childhood, maternal over-
control, and parental psychopathology, have also 
been found to precede the later development of PD 
(53,65,146-148). Childhood sexual, physical, and 
verbal abuse and childhood neglect increase the risk 
for development of PD in adolescence and 
adulthood (65,147,149-152). 
Early disruptive behavior disorders—especially 
conduct disorder but also attention-deficit/hyper-
activity disorder (ADHD) and oppositional defiant 
disorder—are strong long-term predictors for most 
types of PDs (35,65,153-158). The available 
research evidence indicates a link between ADHD 
in childhood and heightened risk of borderline PD 
in adolescence and early adulthood (158-160). Such 
findings might suggest that similar or identical 
phenomena (e.g., impulsivity and aggression) may 
be misleadingly characterized as mental state 
pathology in children and then later relabeled as 
personality pathology in adolescence and adulthood 
(161). 
With regard to antisocial PD, the DSM-5, Section 
II, requires evidence of conduct disorder with onset 
before age of 15 years, in order for this diagnosis to 
be considered applicable to persons aged 18 years or 
older. The available research evidence supports to 
some extend this notion of conduct disorder in 
childhood and adolescence as a developmental 
precursor to antisocial PD (162-164). Yet, it should 
be noted that conduct disorder is also prospectively 
associated with a wide range of other mental 
disorders, including other specific PDs. Hence, the 
predictive value of conduct disorder does not 
appear to be limited to antisocial PD, but rather to a 
broad range of psychopathology including other 
specific PDs, primarily from Cluster B PDs 
(153,154,156,162). Within the externalizing spec-
trum of disorders, substance use disorders 
(particularly alcohol abuse) have also been identified 
as predictors of early adult borderline PD (165). 
With regard to internalizing disorders, major 
depression and anxiety disorder in childhood has 
been prospectively linked with a heightened risk of 
developing PD during young adulthood (155,156). 
Symptoms of social anxiety have also been directly 
linked with avoidant PD (53,155), and some 
investigators argue that generalized social phobia 
and avoidant PD are not separate disorders but 
rather part of a single spectrum (53). 
Few studies have investigated PD in childhood 
and adolescence as a predictor of adult PD using 
prospective longitudinal designs. However, the 
available studies indicate that PD symptoms in 
childhood and adolescence are the strongest long-
term predictors of PD diagnoses in adulthood, over 
and above other predictors such as disruptive 
behavior disorders and depression (23,25,53,55, 
74,78,155). 
Few studies have examined the perinatal factors 
associated with PD. However, for schizotypal PD, 
and to some extend also schizoid PD, studies 
suggest links with prenatal malnutrition, exposure to 
prenatal stress, and influenza (166). 
There is little empirical knowledge about 
resilience and protective factors for PD (167,168). 
One study has investigated the association between 
retrospective accounts of positive childhood 
experiences related to resiliency among adult 
patients with PD and prospective remission from 
avoidant, schizotypal, borderline, and obsessive-
compulsive PD over the course of 4 years (167). 
This study found that positive achievement 
experiences were significantly associated with 
remission from avoidant and schizotypal PD. In 
addition, various types of positive interpersonal 
relationships were associated with remission from 
avoidant, borderline, and schizotypal PD. For 
obsessive-compulsive PD, they found no significant 
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predictors of remission, which the authors speculate 
could be due to the generally higher functioning of 
this group. Although competent parenting is 
considered important for the fostering of resiliency, 
perceived caretaker competence variables in this 
study were not found to be broadly associated with 
remission. The more general finding from the study 
was that the greater the number of positive 
experiences and the broader the developmental 
periods they spanned, the better the prognosis of 
the individuals with PDs (167).  
 
Treatment: Prevention and early intervention 
Whilst diagnosing PD during adolescence is 
evidence based and feasible, there would be little 
point in doing so unless corresponding treatments 
were available. The empirical evaluation of 
treatments has been slow to develop, but this is now 
changing.  
 
Prevention and early intervention: The available data on 
PD in adolescence makes a compelling case for the 
development and implementation of empirically 
based prevention and early intervention programs 
(161,169,170). Like other forms of psycho-
pathology, PD interferes with normative 
development and adaptation. PD can have severe 
repercussions, and its developmental disruptions 
have cascading effects (171-173) that potentially 
alter or divert the entire course of development 
(174). Prevention and early intervention programs 
hold the promise of not only alleviating present 
difficulties but also potentially averting future 
negative outcomes through targeting PD pathology 
before it become more ingrained and chronic (175). 
Chanen and colleagues (161,169,176) have argued 
for applying preventive and early intervention 
strategies to PD during childhood and adolescence 
following the general framework for prevention of 
mental disorders outlined by the Institute of 
Medicine (177). An advantage of this framework is 
that it is not specifically concerned with aetiology, 
onset, and incidence—matters of which we only 
have limited knowledge—but rather focuses on risk 
factors associated with the persistence and 
maintenance of these disorders. Such a framework 
suits our current knowledge and understanding of 
PD. Chanen and colleagues argue that the available 
data do not yet support universal population based 
or selective risk-factor based prevention programs. 
Instead, they argue that indicated prevention and 
early intervention are currently the most feasible 
strategies (161,170,176). In contrast with 
conventional treatment programs that target 
individuals with established PD (i.e., those who 
meet the full criteria), indicated prevention 
programs target children and adolescents who 
display precursor signs and symptoms associated 
with PD (i.e., those who display some but not 
necessarily all of the required PD criteria). Early 
intervention programs aim for the early detection 
and treatment of the full-syndrome disorder. 
Consistent with knowledge on the course and 
development of PD, indicated prevention and early 
intervention programs should not just target the 
diagnostic features of PDs, which might naturally 
attenuate over time; rather, they should aim to 
improve adaptive functioning and alter the 
developmental trajectory of PD. Furthermore, it 
should be noted, that not all treatment that occurs 
for individuals who are less than 18 years old by 
definition is prevention or early intervention 
(161,169,178). For example, it is possible to see a 
15-year-old child with many years of enduring 
personality pathology who is in need of standard 
treatment, and it is also possible to see a never-
treated 24-year-old adult with subsyndromal 
personality pathology who is in need of indicated 
prevention. 
 
Treatment programs: In adult populations, 
psychotherapy remains the treatment of choice for 
PDs (179,180), although most of the evidence is 
limited to borderline PD and antisocial PD. 
Similarly, treatment research on PD in adolescence 
primarily focuses on borderline PD, with most of 
the studies combining indicated prevention 
(subsyndromal cases) and early intervention (full-
syndrome disorder). Of note, only two studies 
(181,182) explicitly included participants who had 
never before been treated for borderline PD (early 
intervention). 
Three randomized controlled trials (RCTs) have 
been conducted to assess the effectiveness of 
cognitive analytic therapy (CAT) for adolescents 
with borderline PD. CAT is an integrative and time-
limited form of psychotherapy that combines object 
relations theory with cognitive psychology. The 
initial study (181) compared the effectiveness of 
adding up to 24 sessions of CAT to the Helping 
Young People Early (HYPE) program (183) versus 
manualized good clinical care (GCC). Seventy-eight 
participants between the ages of 15 and 18 years 
who fulfilled two to nine DSM-IV borderline PD 
criteria completed the trial. No significant 
differences between the two treatment groups with 
regard to predetermined outcomes were found at 24 
months. However, participants in the CAT group 
improved more rapidly. No adverse effects were 
observed for either treatment. Using a quasi-
experimental design, this research group later 
compared the effectiveness of CAT and good 
clinical care (GCC) as determined by their RCT 
with historical data on treatment-as-usual (TAU) in 
PD in Childhood and Adolescence 
 
37 
 
their clinic (182). Results from this study revealed 
that both HYPE with CAT and HYPE with GCC 
were more effective than TAU and that HYPE with 
CAT was the most effective. Recently, a pilot RCT 
(184) have also been conducted to investigate the 
feasibility of treating co-occurring first-episode 
psychosis and borderline PD in adolescents with a 
hybrid treatment model that mixed elements from 
the HYPE with CAT program with a specialized 
first episode psychosis treatment program. The 
preliminary results were promising, suggesting that 
the brief hybrid intervention program was safe and 
acceptable to this complex subgroup of adolescent 
patients. 
Mentalization-based treatment (MBT) has also 
been adapted for adolescents (MBT-A) (185-187). 
An RCT (188) included 80 adolescents (73% of 
whom met full diagnostic criteria for borderline 
PD) who consecutively presented to mental health 
services with self-harm and co-occurring 
depression. Participants were randomly assigned to 
MBT-A or TAU (not manualized). MBT-A is an 
attachment and psychodynamically oriented 
treatment program comprised of weekly individual 
therapy sessions and monthly MBT family groups. 
Results indicated that MBT-A was more effective 
than TAU for reducing self-harm and depression 
and that the superior effectiveness of MBT-A was 
explained by improvements in mentalizing and 
borderline PD features as well as reduced 
attachment avoidance. Further studies of MBT-A 
are underway to investigate the efficacy and 
effectiveness of this treatment for adolescents with 
borderline PD (187,189,190). 
Dialectical behavior therapy (DBT) is another 
treatment that has been implemented for the 
treatment of suicidal and self-harming adolescents 
(DBT-A) displaying features of borderline PD 
(191,192). DBT is a modified form of cognitive-
behavioral therapy that combines cognitive-
behavioral therapy techniques for emotion 
regulation and reality testing with Zen Buddhist and 
mindfulness concepts and techniques (193). The 
only RCT of DBT-A for adolescents with 
borderline PD compared the effectiveness of DBT 
with non-manualized enhanced usual care (EUC) 
for the reduction of self-harm (194). The study 
included 77 self-harming adolescents (of which 21% 
met full criteria for borderline PD) recruited from 
psychiatric outpatient clinics. The results revealed 
that DBT-A was superior to enhanced EUC for 
reducing self-harm, depressive symptoms, and 
suicidal ideation. 
Two RCTs have investigated the effectiveness of 
emotion regulation training (ERT). ERT is a 17-
session adjunctive program, based on the Systems 
Training for Emotional Predictability and Problem 
Solving (STEPPS) program for adults with 
borderline PD (195) that combines group-based 
skills training with family psychoeducation. In both 
studies, the effectiveness of ERT was compared 
with TAU. In the first study (196), 43 adolescents 
were randomized to ERT plus TAU or TAU alone. 
The results revealed a significant decrease in 
borderline PD symptoms in both groups, and there 
was no significant difference between the two 
groups in terms of improvements. In the second 
study (197), 109 participants with features of 
borderline PD (73% met the full criteria for this 
condition) were randomized to ERT plus TAU or 
TAU alone. This study also found no significant 
differences between the two treatment groups. Both 
groups improved equally on measures of borderline 
PD severity, general psychopathology, and quality 
of life. 
 
Psychopharmacological treatment: To our knowledge, the 
only pharmacotherapeutic RCT for adolescents with 
borderline PD was a small (N = 15) post hoc 
subgroup analysis of a larger RCT that investigated 
the effects of long-chain omega-3 (n-3) 
polyunsaturated fatty acids (PUFAs) on functioning 
and psychiatric symptoms among young people 
with borderline PD who also met ultra-high-risk 
criteria for psychosis (198). Results indicated that 
fatty acid (n-3 PUFA) levels at baseline correlated 
positively with psychosocial functioning and 
negatively with psychopathology. At the end of the 
intervention, these fatty acids were associated with 
improved functioning and reduced psychiatric 
symptoms as compared with placebo. 
 
Taking the Dodo Bird serious: effective ingredients and 
common factors: The RCTs just discussed suggest that 
indicated prevention, early intervention, and 
standard treatment programs for borderline PD in 
adolescents are acceptable and effective. It is 
noteworthy that all interventions, including 
manualized TAU and other control treatments, 
were effective. Hence it remains unclear to what 
extent the reported effects can be attributed to 
specific psychotherapeutic interventions (161). Of 
course, control treatments such as TAU or GCC 
should not be equated across studies, and research 
suggests that the choice of comparison treatment 
can considerably influence effect sizes in 
psychotherapy research (199,200), which has also 
been demonstrated in recent RCTs for treatments 
of borderline PD in adult patients (201-205). 
However, a general finding from RCTs for 
treatment of borderline PD in both adolescent and 
adult samples (206) and in reviews and meta-
analyses of psychotherapy outcome research is that 
there is often little or no difference in efficacy 
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among various bona fide psychotherapeutic 
treatments (207-210); a finding commonly referred 
to as the Dodo bird verdict (211). Taken together this 
points toward the importance of common factors, 
extra-therapeutic factors, and placebo effects 
(206,212-216). It may thus be proposed that some 
of the most important factors related to effecting 
change have less to do with the specific techniques 
promoted by the various schools of psychotherapy 
and more to do with the core and common 
elements shared across these various therapies 
(113,161,170,206,217-219). 
On the basis of studies of adults, Fonagy (218) 
and other investigators (179,206,217) have identified 
a number of common features of effective 
treatments for borderline PD in adults, such as: 1) 
considerable efforts to enhance treatment com-
pliance; 2) consistent focus on problem behaviors 
(e.g., self harm) and interpersonal problems; 3) a 
coherent conceptual theory, framework, and 
language for the patient and the therapist/staff to 
share; 4) encouragement of a supportive attachment 
relationship between the therapist and the patient 
that is of relatively long duration; and 5) that the 
treatment is highly structured and well integrated 
with other services that the patient uses. 
Recently, Chanen and colleagues (161,170) 
extended this line of reasoning to adolescents by 
identifying potential (common) key ingredients in 
effective prevention and early intervention 
programs for borderline PD – including factors 
beyond individual psychotherapy related to models 
of service delivery. Among other things, they 
highlighted the importance of the following 
features: 1) assertive and psychologically informed 
case management integrated with the delivery of 
psychotherapy; 2) the capacity for outreach care 
into the community; 3) the active engagement and 
inclusion of family members and carers in the 
treatment process, including psychoeducation and 
brief family interventions delivered in accordance 
with the overall treatment model; 4) the consistent 
use of a plain and common language based on a 
shared model of the self and the psychopathology 
across all aspects of care; 5) the integration of 
general psychiatric care within the specialist 
treatment team, including assessment and treatment 
of co-occurring disorders; 6) the presence of a crisis 
team and availability of inpatient care programs with 
clear and time-limited goals; 7) access to a 
psychosocial recovery program; and 8) regular 
supervision of staff and quality assurance. Elements 
such as those highlighted by Chanen and colleagues 
must be implicated in our future understanding of 
why structured treatments, including those in the 
control conditions of the RCTs, for adolescents 
with borderline PD appear to be equally effective. 
In passing it should be noted, that many of the key 
elements highlighted by Chanen and colleagues 
(161) are also identified and used in the adolescent 
mentalization-based integrative therapy (AMBIT) 
approach to hard-to-reach adolescents with multiple 
mental health problems and vulnerabilities 
(220,221). This could indicate that they have wider 
applicability beyond borderline PD, for manage-
ment and treatment of youth with complex 
psychopathology. 
 
First, do no harm: dropout and iatrogenic harm: A more 
disheartening finding from the previously described 
RCTs for borderline PD in adolescence is that the 
dropout rates appear to be relatively high across the 
studies and in both the treatment and control 
groups (181,188,194,196,197). As a result of 
differences in defining and reporting dropout in the 
trials, it is not possible to compute and compare 
exact estimates of dropout rates across the trials and 
treatment conditions. But based on the published 
data from these RCTs, there are indications that 
approximately 20% to 54% of the participants 
appear to dropout of treatment prematurely. More 
generally, it is estimated that 20% to 70% of 
persons, across all age groups and diagnoses, who 
begin psychosocial mental health treatment 
discontinue such treatment against their clinicians’ 
recommendations (222). For adolescents specific-
ally, a study suggests that about a third of patients in 
mental health psychosocial treatments dropout 
prematurely (223). A systematic review that included 
25 studies of non-completion among PD treatments 
found a median non-completion rate of 37% (224). 
Taken together, such data suggest that dropout or 
premature termination from psychotherapy is a 
major challenge that should be addressed explicitly 
in future treatment research. 
Another important issue to consider is the 
iatrogenic or harmful effects of therapies. Both 
quantitative and qualitative reviews find that around 
75% to 80% of those individuals treated with 
psychotherapy benefit from it (225,226). However, 
a somewhat neglected but crucial finding of such 
reviews is that 5% to 10% of those who participate 
in treatment trials get worse. For child psycho-
therapy, these numbers may be even higher, with up 
to 24% of children between the ages of 4 and 17 
years who are treated in community mental health 
settings deteriorating (227). A recent uncontrolled 
treatment study of adolescent inpatients with PD 
found that 26% of the participants showed reliable 
change and moved into a normative range of 
symptom severity; the rest of the participants did 
not change or only displayed modest symptom 
reduction, and 9% deteriorated (228). Data from an 
RCT study of CAT for PD in adults have also 
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demonstrated that TAU can act as a “nocebo” 
condition in which harmful effects arise from a 
placebo treatment (161,229,230). Furthermore, 
studies have demonstrated that therapists are not 
good at predicting patients’ outcomes or at 
determining patients’ perceptions of the quality of 
the therapeutic relationship or of group relation-
ships; the therapists tend to underestimate the 
number of patients who are deteriorating during 
therapy (231-233). Research has also consistently 
demonstrated that the therapeutic alliance is one of 
the most consistent and robust predictors of 
therapeutic outcome (234,235) and that it is 
therapist variability—rather than patient 
variability—that brings about most of this alliance–
outcome association (234,236). Moreover, 
intervention research suggests that focusing on the 
therapeutic relationship or transference seems to 
have the strongest effect for patients with 
personality problems within the context of a weak 
alliance (237-239), whereas it can have negative 
effects for patients without personality problems 
and in the context of a strong alliance (240). Taken 
together, these data make a compelling case for 
implementing routine outcome monitoring systems 
in the treatment of PD so that clinicians can 
respond adequately and flexible if progress is 
lacking or when signs of deterioration become 
apparent (113,233,241,242). 
 
Conclusions and clinical implications 
On the basis of the preceding selected review of the 
available research evidence, the following 
conclusions and clinical implications can be drawn 
with regard to PD in adolescence:  
 PD can be diagnosed as reliable and valid in 
adolescents as in adults. 
 The point prevalence of PD diagnoses 
peaks in early adolescence and then 
declines reaching estimates comparable to 
those for adults by late adolescence.  
 Studies suggest that 41% to 64% of 
adolescents in clinical settings meets 
diagnostic criteria for PDs, indicating they 
are highly prevalent 
 Co-occurrence between PDs is frequent.  
 PD changes from childhood through adult-
hood in similar ways to normal-range 
personality. In adolescence, as in adult-
hood, the rank order stability of PD is 
moderate to high, whereas diagnostic 
stability is low.  
 The functional impairments associated with 
PD are stable across the lifespan.  
 PD co-occurring with other mental dis-
orders is frequent, and associated with a 
poorer prognosis. 
 PD is associated with considerable treat-
ment needs and mental health service use. 
 RCTs show that indicated prevention and 
early intervention programs are promising 
and effective for adolescents with border-
line PD. 
 There is currently no evidence to support 
the superiority of one treatment over an-
other for adolescents with borderline PD. 
 Considering the very limited evidence for 
the psychopharmacological treatment of 
PD in adolescence (and even during adult-
hood), this type of treatment cannot be re-
commended at present.  
 
Hume’s Guillotine: Barriers and Potential Risks 
Although diagnosing PD during adolescence is 
feasible, this does not necessarily imply that one 
ought to diagnose it during this period. As the 
moral philosopher David Hume (243) pointed out 
long ago, one cannot automatically make a 
normative claim solely based on facts: in moral 
matters, claims of what is must be severed from 
claims about what ought to be. Indeed, mental health 
professionals who work with children and 
adolescents often report concerns about stigma as a 
reason for not using PD diagnoses (20). Researchers 
and clinicians should always be wary of the potential 
harmful effects of diagnostic labeling. PD 
generally—and borderline and antisocial (including 
psychopathy) PD more specifically—are stigmatized 
among some mental health professionals, patients, 
the judicial system, and society at large (244-247). 
However, well-intentioned clinicians who purpose-
fully refrain from using PD diagnoses with 
adolescent patients in order to avoid stigma or 
discrimination may thereby unwittingly be 
reinforcing and perpetuating the very stigma that 
they wish to avoid (170). This in turn may increase 
the risk of inappropriate diagnosis and iatrogenic 
harm (e.g., from polypharmacy), which may hinder 
young people from receiving targeted evidence-
based treatment (170). We propose that, on balance, 
the potential harmful effects of labeling young 
people via the diagnosis of PD are outweighed by 
the risk of them not receiving appropriate 
treatment. In our clinical experience, most patients 
and families welcome the diagnosis and the implicit 
acknowledgement of their difficulties and needs. 
Arguably, evidence-based prevention and early 
intervention programs for these conditions may also 
prove to be cost-effective for society at large (124). 
This favorable disposition toward early detection 
and intervention through a diagnosis of PD during 
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adolescence is also reflected in national guidelines 
(6,7), alternative classification models (60,98,248), 
and is likely to be included in the forthcoming ICD-
11 (249). 
Although we are enthusiastic about these 
developments within the field, it should also be 
recognized that the removal of age-related caveats 
from the diagnostic criteria for PD will in all 
likelihood lead to more young people being 
diagnosed and treated, and some of these 
individuals may not meet the full criteria for PD 
(i.e., they may exhibit subthreshold PD) (22). In this 
context, we need to recognize that the potential 
benefits arising from such changes will need to be 
weighed against the potential risks, such as the 
“medicalizing” of common or normative problems, 
as well as the problems associated with over-
treatment, side effects, stigma, and iatrogenic harm 
(169,250). 
 
Future Research 
Although the current evidence converges to support 
the clinical utility and feasibility of diagnosing PD in 
adolescence, it also reveals the limitations inherent 
to our current diagnostic systems. Despite the 
similarities between the adolescent and adult PD 
phenotypes, it is important to note that these 
diagnostic categories were originally derived from 
descriptions of adult patients. Hence, the downward 
extension of these diagnoses runs the risk of 
“adultomorphizing” (251) PD during childhood and 
adolescence, potentially not encompassing the 
whole domain of preadult personality pathology 
during childhood and adolescence (60,98,252,253). 
Both the DSM-5 (Section III, alternative PD 
classification system) and the ICD-11 proposal for 
PD classification are promising because they 
incorporate developmental evidence regarding PD 
in adolescence, remove age criteria, and take a 
dimensional approach to classification (10,249,254). 
These alternative classification schemes combine a 
dimensional approach with ratings of impairment in 
personality functioning and/or severity. Improve-
ment in the classification of PD is likely to lead to 
improvements in the design and delivery of 
effective prevention and early intervention 
programs (4,22). 
In an effort to extend contemporary approaches 
to the classification of PD, we propose a 
transdiagnostic clinical staging approach (255), 
eschewing diagnostic syndrome categories and 
arbitrary age criteria in favor of focusing on defining 
the stage of progression of PD at a particular point 
in time, and assessing symptom severity and 
persistence, need for care, and the proportionality 
of treatment interventions (256). The clinical staging 
approach to PD (257,258) attends to where an 
individual is currently placed on the continuum of 
the course of PD. The individual’s treatment needs 
and the severity of PD will differ as a function of 
the stage or progression of the disorder, with 
treatment in theory being more benign (i.e., less 
intensive and invasive) and effective during the early 
stages (170). In accordance with this approach and 
its inherently transdiagnostic nature, the task for 
future research is to identify and describe a range of 
risk syndromes for the later development of 
psychopathology. Such risk syndromes can act as 
indicators for preventive and early intervention 
programs (259). 
Prospective studies are required to advance our 
understanding of the course of the full range of 
personality pathology throughout the life span and 
to counter our current overreliance on data from 
the CIC Study. The meta-theoretical framework of 
developmental psychopathology could be used in 
the design of such studies (80,81). Moreover, we 
need greater knowledge on continuity and change 
dynamics, different developmental trajectories, and 
risk and protective factors associated with both 
adaptive and maladaptive development, including 
pathogenesis and salutogenesis. Future studies must 
include infants or children, and should ideally 
incorporate genetic/biological, individual, and 
environmental/societal factors into their designs. 
This would further our understanding of the 
factors, dynamics, and risk syndromes that are 
prospectively associated with onset, development, 
and maintenance of PD, as well as of the factors 
and processes associated with resilience and 
remission. 
Although results from the available RCTs are 
promising, we still need follow-up data from these 
to evaluate whether they effectively alter the life 
course trajectory of PD and lead to stable 
improvements in functioning over time. Pro-
spectively improving quality of life and adaptive 
functioning should indeed be the main aims of 
future prevention and early intervention programs 
targeting PD in adolescence. Improving patient 
retention in the treatment programs and reducing 
iatrogenic harm are also high priorities for future 
research to address. The use of client feedback and 
outcome tracking systems has been shown to be 
effective in psychotherapy research (260) for the 
reduction of the harmful effects of treatments. We 
therefore hypothesize that this could also be the 
case for the treatment of PD in childhood and 
adolescence. Moreover, the future development of 
novel prevention and early interventions programs 
targeting PD in adolescence should focus more on 
common factors and effective ingredients rather 
than specific “brand name” psychotherapies 
(161,179,261). This would include targeting both the 
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young person as well as that person’s environment, 
including his or her family members and other 
relevant systems. Research is also needed to identify 
those subgroups that do not benefit from treatment 
or deteriorates, so that we can prevent adverse 
effects and develop new interventions for the non-
responders. Finally, we recommend that future 
research focus on relatively simple treatment 
programs to enhance the external validity of those 
programs, thereby enabling their implementation in 
routine clinical practice so that they might ultimately 
lessen the burden of PDs on individuals, families, 
and society. 
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